Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review

Le, Bao Han A.; Kim, Jonathan W.; Deng, Hao; Rayess, Nadim; Jennelle, R.; Zhou, Sue Y.; Astrahan, Melvin A.; Berry, Jesse L.

doi:10.1016/j.brachy.2018.07.002

Cited by 37 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the median size of treated tumor was 4.7 mm in depth and additional treatment to improve final visual results were used. The 3-year visual acuity of more than 20/200 was reported from 45 to 73% in several studies after 125 I plaque brachytherapy [ 15 – 17 ]. In our study, the preservation of useful vision (more than 20/200) was achieved in 66.7% of patients after a median follow-up of 61.5 months, and 52.2% of patients (total number of 12) kept their initial visual acuity better than 20/40 after the treatment.…”

Section: Discussionmentioning

confidence: 99%

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

et al. 2020

View full text Add to dashboard Cite

Background: To evaluate 106 Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. Methods: From April 2007 to October 2015, 39 patients with medium sized uveal melanoma were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7 mm (±SD:1.6 mm). The mean dose at the tumor apex was 141.4 Gy (± SD: 12.1 Gy) and 557.7 Gy (± SD: 257.3 Gy) to the sclera. Results: Mean follow-up was 69.5 months (± SD: 53.8 months). Thirty-four patients (87.1%) remained free of recurrence. Twenty-six patients (66.7%) demonstrated a complete tumor regression after a median period of 12 months (3-60 mon.). By the final examination, the visual acuity of 26 patients (66.7%) was better than 20/200, and 12 patients (30.7%) had a visual acuity better than 20/40. Retinopathy was detected in 11 patients (28.2%). After treatments only one patient (5.1%) had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 patients (10.3%). Cataract development was diagnosed in 21 patients (53.8%), and 16 patients (41%) had bilateral cataract development. Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5 mm or more. There was no significant difference in local control or in side effects between both groups observed. Conclusions: Our study proved 106 Ru-brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. Our data suggested that this treatment is also suitable for tumors with a depth of more than 5 mm.

show abstract

Section: Discussionmentioning

confidence: 99%

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The median size of treated tumor depth was 4.7 mm and additional treatment to improve final visual results were used [13]. The 3-years visual acuity of more than 20/200 was reported from 45%-73% in several studies after 125 I plaque brachytherapy [14,15,16]. In our study, the preservation of useful vision (more than 20/200) was achieved in 66.7% of patients after a median follow-up of 61.5 months.…”

Section: Discussionmentioning

confidence: 99%

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

Jiang

Purtskhvanidze

Kandzia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To evaluate 106Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity.Methods: From 2007 to 2015, 39 patients were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the median tumor depth was 3.0 mm (CI: 1.6-8.9 mm). Median dose at the apex of the tumor was 145 Gy (± SD: 12.1Gy). The median sclera dose was 444.0Gy (±SD: 257.3 Gy). Results: Median follow-up was 61.5 months (CI: 8.1-138 mon.). 34 patients (87.1%) remained free of recurrence. In 26 (66.7%) patients a total regression was achieved after a median period of 12 months (CI: 3-60 mon.). By the final examination, the visual acuity of 26 (66.7%) patients was better than 20/200. 12 (30.7%) patients had a visual acuity better than 20/40.Retinopathy was detected in 11 (28.2%) patients. After treatments only 1 (5.1%) patients had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 (10.3%) patients. Cataract development was diagnosed in 21 (53.8%) patients, although 16 (41%) of them had bilateral cataract development.Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5mm or more. There was no significant difference neither in local control (75 % in tumors ≥5mm versus 92.6 % in tumors <5mm) nor in side effects between both groups. Conclusions: Our study proved 106 Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. The data suggest that this treatment is also suitable for tumors with a depth of more than 5mm.

show abstract

“…The median size of treated tumor depth was 4.7mm and additional treatment to improve nal visual results were used [14]. The 3-years visual acuity of more than 20/200 was reported from 45%-73% in several studies after 125 I plaque brachytherapy [15,16,17]. In our study, the preservation of useful vision (more than 20/200) was achieved in 66.7% of patients after a median follow-up of 61.5 months.…”

Section: Patient Characteristicsmentioning

confidence: 99%

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

Jiang

Purtskhvanidze

Kandzia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To evaluate 106 Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. Methods: From 2007 to 2015, 39 patients were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7 mm (±SD:1.6). Mean dose at the apex of the tumor was 141.4 Gy (± SD: 12.1 Gy). The mean sclera dose was 557.7 Gy (± SD: 257.3 Gy). Results: Mean follow-up was 69.5 months (± SD: 53.8 months). 34 patients (87.1%) remained free of recurrence. In 26 (66.7%) patients a total regression was achieved after a median period of 12 months (Range: 3-60 mon.). By the final examination, the visual acuity of 26 (66.7%) patients was better than 20/200. 12 (30.7%) patients had a visual acuity better than 20/40. Retinopathy was detected in 11 (28.2%) patients. After treatments only 1 (5.1%) patients had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 (10.3%) patients. Cataract development was diagnosed in 21 (53.8%) patients, although 16 (41%) of them had bilateral cataract development. Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5mm or more. There was no significant difference neither in local control (75 % in tumors ≥5mm versus 92.6 % in tumors <5mm) nor in side effects between both groups. Conclusions: Our study proved 106 Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. The data suggest that this treatment is also suitable for tumors with a depth of more than 5mm.

show abstract

Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review

Cited by 37 publications

References 41 publications

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

Contact Info

Product

Resources

About